Autolus Therapeutics (6A3A) Stock Statistics & Valuation Metrics

Autolus Therapeutics has a market cap or net worth of EUR 361.72M. The enterprise value is EUR 590.54M.

Market Cap

EUR 361.72M

Enterprise Value

EUR 590.54M

Autolus Therapeutics has 266,162,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

266,162,540

Owned by Insiders

<0.01%

Owned by Institutions

2.38%

Autolus Therapeutics’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -51.54%.

Return on Equity (ROE)

-1.62

Return on Assets (ROA)

-0.49

Return on Invested Capital (ROIC)

-51.54%

Return on Capital Employed (ROCE)

-0.55

Revenue Per Employee

100.48K

Profits Per Employee

-383.24K

Employee Count

752

Asset Turnover

0.13

Inventory Turnover

2.91

The current PE Ratio of Autolus Therapeutics is -1.34. Autolus Therapeutics’s PEG ratio is 0.05.

PE Ratio

-1.34

PS Ratio

3.22

PB Ratio

5.05

Price to FCF

-1.59

Price to Operating Cash Flow

-1.68

PEG Ratio

0.05

In the last 12 months, Autolus Therapeutics had revenue of 75.56M and earned -288.20M in profits. Earnings per share was -1.08.

Revenue

75.56M

Gross Profit

-21.03M

Operating Income

-281.44M

Pretax Income

-296.85M

Net Income

-288.20M

EBITDA

-250.28M

Earnings Per Share (EPS)

-1.08

In the last 12 months, operating cash flow was -225.61M and capital expenditures -11.84M, giving a free cash flow of -237.45M billion.

Operating Cash Flow

-225.61M

Free Cash Flow

-237.45M

Free Cash Flow per Share

-0.89

Autolus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-63.00%

Earnings Yield

-74.30%

Beta

1.60

52-Week Price Change

6.20%

50-Day Moving Average

1.66

200-Day Moving Average

1.44

Relative Strength Index (RSI)

39.26

Average Volume (3m)

437

Autolus Therapeutics upcoming earnings date is Nov 10, 2026, Before Open (Not Confirmed).

Last Earnings Date

Aug 11, 2026

Next Earnings Date

Nov 10, 2026

Ex-Dividend Date

―

Autolus Therapeutics as a current ratio of 5.94, with Debt / Equity ratio of 197.38%

Current Ratio

5.94

Quick Ratio

5.48

Debt to Market Cap

0.54

Net Debt to EBITDA

-0.99

Interest Coverage Ratio

-7.66

In the past 12 months, Autolus Therapeutics has paid -8.65M in taxes.

Income Tax

-8.65M

Effective Tax Rate

0.03

Autolus Therapeutics EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.22.

EV to Sales

2.46

EV to EBITDA

-1.31

EV to Free Cash Flow

-1.22

EV to Operating Cash Flow

-1.28

Autolus Therapeutics has EUR 201.63M in cash and marketable securities with EUR 83.51M in debt, giving a net cash position of EUR 118.12M billion.

Cash & Marketable Securities

EUR 201.63M

Total Debt

EUR 83.51M

Net Cash

EUR 118.12M

Net Cash Per Share

EUR 0.44

Tangible Book Value Per Share

EUR 0.21

Gross margin is 15.66%, with operating margin of -210.76%, and net profit margin of -238.62%.

Gross Margin

15.66%

Operating Margin

-210.76%

Pretax Margin

-238.04%

Net Profit Margin

-238.62%

EBITDA Margin

-188.22%

EBIT Margin

-197.90%

The average price target for Autolus Therapeutics is EUR 6.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

EUR 6.88

Price Target Upside

402.53% Upside

Analyst Consensus

Strong Buy

Analyst Count

5

Revenue Growth Forecast

272.71%

EPS Growth Forecast

-14.59%

Smart Score

4

AI Score

―